Phase-I/IIa study of radiofrequency ablation combined with in situ application of immune adjuvant for hepatocellular carcinoma

Phase-I/IIa study of radiofrequency ablation combined with in situ application of immune adjuvant for hepatocellular carcinoma - RFA+ISAIA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000052

Enrollment

Registered

2008-07-01

Start date

2005-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Adjuvant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced hepatocellular carcinoma

Exclusion criteria

Exclusion criteria: Immunodeficiency

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026